Volume 7 Supplement 1

Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

Effect of immunodeficiency and tumor marker expression on HIV-related diffuse large B-cell lymphoma prognosis

  • Michael J Silverberg1Email author,
  • Jonathan Said2,
  • Hongbin D Zha3,
  • Donald I Abrams2, 4,
  • Otoniel Martinez-Maza2,
  • Michelle McGuire3,
  • Reina Haque3,
  • Margaret Chi3,
  • Lanfang Xu3,
  • Brandon Castor2 and
  • Chun Chao3
Infectious Agents and Cancer20127(Suppl 1):P47

https://doi.org/10.1186/1750-9378-7-S1-P47

Published: 19 April 2012

Background

Several tumor markers may predict survival in HIV+ patients with diffuse large B-cell lymphoma (DLBCL). Here, we evaluate the association of immunodeficiency (CD4<200) on expression of prognostic tumor markers and survival.

Methods

HIV+ DLBCL cases diagnosed between 1996-2007 within Kaiser Permanente California were identified. H&E slides were reviewed to identify representative tumor blocks for tissue microarray (TMA) construction. Immunohistochemistry staining of TMA cores was used to detect the expression of selected markers in the categories of (1) cell cycle regulators, (2) B-cell activators, (3) anti-apoptotic proteins, and (4) others, including Epstein Barr Virus (EBV). Percent of DLBCL cells with visible marker staining was scored on a scale from 0-4 (i.e., 0-9%, 10-24%, 25-49%, 50-74% and ≥75%). EBV infection was determined by in situ hybridization of EBV RNA. We also considered high vs. low expression levels based on previously established cut-offs. Of the 20 markers previously examined, three had emerged as significant predictors of survival, including EBV, cMYC and BLIMP1. Here, we evaluated the association between CD4 and expression of these three markers by t-test for mean levels and chi-square for % high levels. We also evaluated the combined effect of immunodeficiency and marker expression on 2-year survival in unadjusted Cox models.

Results

We identified 194 HIV+ DLBCL cases; 80 patients had adequate tissue for the marker analyses. Of the three markers, only EBV was associated with CD4 level (Table 1).
Table 1

Tumor marker levels by CD4

 

EBV

cMYC

BLIMP1

 

CD4

 

CD4

 

CD4

 
 

<200

≥200

P

<200

≥200

P

<200

≥200

P

Mean levels

1.9

0.6

0.009

1.6

1.7

0.90

0.3

0.2

0.65

% high levels

45.7

16.0

0.016

68.6

64.0

0.71

11.1

8.0

0.69

Survival was lowest in cases with high levels of EBV or cMYC in combination with low CD4 (Table 2). Survival was not evaluated for BLIMP1 given the low prevalence.
Table 2

Two-year survival by CD4 and marker levels

 

EBV

cMYC

 

HR

95% CI

P

HR

95% CI

P

Low CD4/high marker

4.0

1.6-10.2

0.004

3.3

1.0-11.5

0.057

Low CD4/low marker

1.8

0.7-4.9

0.236

1.0

0.2-4.8

0.970

High CD4/high marker

1.6

0.3-7.7

0.557

1.3

0.3-5.1

0.739

High CD4/low marker (ref)

1.0

-

-

1.0

-

-

Conclusion

Immunodeficiency was associated with EBV+ DLBCL. Cases with low CD4 and high levels of EBV or cMYC had worse survival. Risk stratification may consider both CD4 and tumor marker expression, although confirmation is needed in larger studies.

Authors’ Affiliations

(1)
Kaiser Permanente Northern California
(2)
University of California
(3)
Kaiser Permanente Southern California
(4)
San Francisco General Hospital

Copyright

© Silverberg et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement